PepGen Inc.

NasdaqGS PEPG

PepGen Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.06

PepGen Inc. Revenue Per Share is USD 0.06 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

PepGen Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
PepGen Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
PepGen Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

NasdaqGS: PEPG

PepGen Inc.

CEO	Dr. James G. McArthur Ph.D.
IPO Date	May 6, 2022
Location	United States
Headquarters	245 Main Street
Employees	76
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years